Table 3 MACCE of In-Hospital and 12-Months Follow-Up
Variables | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|---|---|---|---|---|
MACE in hospital | ||||
All-cause mortality, n(%) | 1 (0.6%) | 1 (0.6%) | 2 (1.1%) | 0.848 |
MI, n(%) | 2 (1.2%) | 1 (0.6%) | 2 (1.1%) | 0.749 |
Stent thrombosis, n(%) | 1 (0.6%) | 2 (1.1%) | 4 (2.3%) | 0.465 |
Stroke, n(%) | 1 (0.6%) | 1 (0.6%) | 1 (0.6%) | 1 |
TVR, n(%) | 3 (1.8%) | 2 (1.1%) | 7 (4.0%) | 0.213 |
Overall MACCE, n(%) | 5 (2.9%) | 5 (2.8%) | 9 (5.1%) | 0.454 |
MACE during 12-month follow-up | ||||
All-cause mortality, n(%) | 2 (1.2%) | 1 (0.6%) | 2 (1.1%) | 0.749 |
MI, n(%) | 2 (1.2%) | 3 (1.7%) | 5 (2.8%) | 0.576 |
Stent thrombosis, n(%) | 4 (2.3%) | 4 (2.2%) | 6 (3.4%) | 0.792 |
Stroke, n(%) | 1 (0.6%) | 0 | 1 (0.6%) | 0.551 |
TVR, n(%) | 4 (2.3%) | 5 (2.8%) | 13 (7.4%) | 0.047 |
Overall MACCE, n(%) | 11 (6.4%) | 13 (7.3%) | 25 (14.2%) | 0.023 |